Exposure-time-varying hazard function ratios in case-control studies of drug effects

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 2, 2006, Pages 81-92

  Guess, Harry A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Adverse drug reaction; Pharmacoepidemiology; Survival analysis

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE; ENALAPRIL; ESTROGEN; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL CRAMP; ALGORITHM; ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COHORT ANALYSIS; COMPUTER MODEL; COMPUTER PROGRAM; CORRELATION ANALYSIS; DATA ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FOLLOW UP; HAZARD ASSESSMENT; HIGH RISK POPULATION; HUMAN; INCIDENCE; MEDICAL PRACTICE; MORTALITY; PATIENT COMPLIANCE; PEPTIC ULCER; PHARMACOEPIDEMIOLOGY; POISSON DISTRIBUTION; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

CASE-CONTROL STUDIES; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY; EPIDEMIOLOGIC RESEARCH DESIGN; HUMANS; ODDS RATIO; PHARMACOEPIDEMIOLOGY; PROPORTIONAL HAZARDS MODELS; TIME FACTORS;

EID: 33644629845     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1164     Document Type: Article

References (38)

1. Guess HA. Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time. J Clin Epidemiol 1989; 42(12): 1179-1184.
2. Jones JK. Determining causation from case reports. Chapter 32. In Pharmacoepidemiology (3rd edn), Strom BL (ed.). John Wiley & Sons: New York, 2000: 525-538.
3. Kaplowitz N. Presentation at FDA/PhRMA conference on drug-induced liver disease. 12-13 Feb 2001. Available at: http://www.fda.gov/cder/livertox/. [Accessed 16 April 2005].
4. Chemocare.com. Available at: http://www.chemocare.com/bio/bio.sps?iBiographyID=7964. [Accessed 16 April 2005].
5. Grady D, Ernster VL. Endometrial Cancer. Chapter 49. In Cancer Epidemiology and Prevention (2nd edn), Schottenfeld D, Fraumeni JF, Jr. (eds). Oxford University Press: New York, 1996:1058-1089.
6. t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Dujin CM, Stijnen T, Breteler MM, Stricker BH. Non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease. NEJM 2001; 345: 1515-1521.
7. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-737. Erratum in: J Clin Epidemiol 2004; 57: 111.
8. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260(7): 967-970.
9. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141(6): 539-545.
10. Hulley S. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
11. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980; 303: 1038-1041.
12. Joseph KS. The evolution of clinical practice and time trends in drug effects. J Clin Epidemiol 1994; 47: 593-598.
13. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol 2003; 158: 915-920.
14. Feinstein AR. Clinical biostatistics. XI. Sources of 'chronology bias' in cohort statistics. Clin Pharmacol Ther 1971; 12: 864-879.
15. Mantel N. Avoidance of bias in cohort studies. Natl Cancer Inst Monogr 1985; 67: 169-173.
16. McMahon AD, MacDonald TM. Design issues for drug epidemiology. Br J Clin Pharmacol 2000; 50: 419-425.
17. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10: 1100- 1120.
18. Cleves M. How do I analyze multiple failure time data using Stata? Stata FAQs 1999. Available at: http://www.stata.com/support/faqs/stat/stmfail.html. [Accessed 3 September 2005].
19. Leffondre K, Abrahamowicz M, Siemiatycki J. Evaluation of Cox's model and logistic regression for matched case-control data with time-dependent covariates: a simulation study. Stat Med 2003; 22: 3781-3794.
20. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. John Wiley & Sons: New York, 1980.
21. Sheth S. Safety. Presentation at FDA Cardiovascular and Renal Advisory Committee. Slide 21. 10 September 2004 available at: http://www.fda.gov/ohrms/dockets/ac/cderO4.html#cardiovascularRenaL [Accessed 3 September 2005].
22. Rothman KJ, Greenland S. Case-control studies. Chapter 7. In Modern Epidemiology (2nd edn), Rothman KJ, Greenland S (eds). Lippincott-Raven: Philadelphia, 1998; 93-114.
23. Hemmelgarn B, Suissa S, Huang A, Bovin JF, Pinard G. use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278: 27-31.
24. Wegman EJ, Wright IW. Splines in statistics. J Am Stat Assoc 1983; 78: 351-365.
25. Smith PL. Splines as a useful and convenient statistical tool. Am Stat 1979; 33: 57-62.
26. Hastie TJ, Tibshirani RJ. Chapter 3. Smoothing in detail. In Generalized Additive Models. Chapman and Hall: New York, 1990; 39-81.
27. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-146.
28. Hess KR. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med 1994; 13: 1045-1062.
29. Greenland S. Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology 1995; 6: 450-454.
30. Hauptmann M, Wellmann J, Lubin JH, Rosenberg PS, Kreienbrock L. Analysis of exposure-time-response relationships using a spline weight function. Biometrics 2000; 56: 1105-1108.
31. Stone CJ, Koo CY. Additive splines in statistics. ASA Proc Stat Comput Sect 1985; 45-48.
32. Stone CJ. Comments on "Generalized additive models". Stat Sci 1986; 1: 312-314.
33. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8(5): 551-561.
34. Brenner H, Blettner M. Controlling for continuous confounders in epidemiologic research. Epidemiology 1997; 8: 429-434.
35. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6: 356-365.
36. Herndon JE, II, Harrell FE, Jr. The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables. Stat Med 1995; 14: 2119-2129.
37. Weinberg CR. How bad is categorization? Epidemiology 1995; 6: 345-347.
38. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women's health initiative clinical trial. Am J Epidemiol 2005; 162(5): 404-414.